Applied Filters
Fed Circuit overturns Apotex’s PTAB victory
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
Bausch targets Sandoz over IBS generic
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug.
FDA and DEA warn over sale of misbranded opioid drugs
The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.
UK parliament report reveals threat to medical supplies post-Brexit
An independent parliamentary report has today, September 27, revealed that the UK’s health ministry remains unsure whether the country’s health service can fully withstand the impact of a no-deal Brexit next month.
China awards generics contracts to lowest bidders
China’s drug pricing overhaul has seen the average cost of drugs drop by more than half, the country’s Joint Procurement Office announced this week.
UK Labour promises public generics company, compulsory drug licensing
Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.
US Senators urge FTC to closely scrutinise pharma mergers
A group of senators has urged the US Federal Trade Commission to closely scrutinise mergers in the pharmaceutical industry, which it said “increase competition issues and stifle innovation”.
Duke and Allergan escape antitrust claims in Akorn suit
A US judge dismissed antitrust counterclaims brought against Allergan and Duke University earlier this week, in a lawsuit the pair filed against generics maker Akorn.
AIPPI World Congress 2019: SPC and PTEs around the world
This week at the AIPPI World Congress 2019, counsel discussed how supplementary protection certificates and patent term extension regulations differ across jurisdictions.
Vectura wins additional $10m patent damages against GSK
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
